UP FRONT
ASH Webinars
ASH regularly hosts educational webinars that feature presentations by experts in the
field, cover current information on how to best diagnose and care for patients, and
provide time for speakers and participants to discuss relevant issues during a questionand-answer session.
Recordings of ASH Webinars are available at ASH On Demand.
Visit ashondemand.org/Webinars or scan the QR code to the
right to access them.
Webinars recently added to ASH On Demand include:
• The FDA’s accelerated approval of daratumumab to treat patients with multiple
myeloma who have received at least three prior treatments. Daratumumab is the
first monoclonal antibody approved for treating multiple myeloma. The speakers
included: Mikkael Sekeres, MD, director, Leukemia Program, professor of medicine, Cleveland Clinic, Cleveland, OH; Nicole Gormley, MD, acting clinical team
lead, scientific liaison for multiple myeloma, Division of Hematology Products,
U.S. Food and Drug Administration, Silver Spring, MD; and Paul G. Richardson,
MD, RJ Corman Professor of Medicine, Harvard Medical School, clinical program
leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, DanaFarber Cancer Institute, Boston, MA.
• The FDA approval of ixazomib in combination with two other therapies to treat
people with multiple myeloma who have received at least one prior therapy. Ixazomib is the first oral proteasome inhibitor and is approved in combination with
lenalidomide and dexamethasone (a type of corticosteroid). The speakers included:
David Steensma, MD, Dana-Farber Cancer Institute, Division of Hematological
Malignancies, Boston, MA; Alexandria Schwarsin, MD, medical officer, U.S. Food
and Drug Administration, Silver Spring, MD; and S. Vincent Rajkumar, MD, Edward W. and Betty Knight Scripps Professor of Medicine, Division of Hematology,
Mayo Clinic, Rochester, MN.
Look for two upcoming webinar topics to be added to ASH On Demand in late August:
ASH/FDA Update on Nivolumab and ASH/FDA Update on Venetoclax.
ASH Endorses Guideline on Care Models for
Hemophilia Management
Published in Haemophilia on June 27, 2016, the National Hemophilia Foundation–McMaster University Guideline on Care Models for Hemophilia Management was developed to identify evidence-based best practices in hemophilia care delivery, following
specific methods and based on the GRADE (Grading of Recommendations, Assessment,
Development and
Evaluation)
approach.
This guideline
was endorsed by
ASH on May 27,
2016. Access the
newly published
guideline from the
ASH website at
hematology.org/
Clinicians/
GuidelinesQuality/3127.aspx.
ASHClinicalNews.org
ASH Data-Sharing Initiative Featured at
National Cancer Moonshot Summit
In late June, ASH joined Vice President Joe Biden’s National Cancer
Moonshot Summit, a day-long conference intended to jumpstart the
Administration’s effort to double the pace of cancer research. ASH is
helping to encourage cancer researchers to share data, with the goal
of establishing a robust infrastructure of shared multiple myeloma
data that will inform better understanding and treatment of this cancer and serve as a model for others.
ASH joined oncology experts from professional, clinical, and
research organizations at Howard University in Washington, DC, to
foster collaborations around the goals of the National